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Abstract
The focal form of congenital hyperinsulinism (CHI) is characterized by a cluster of abnormal insulin-oversecreting β cells
within a restricted area of the pancreas. Although identification of the focal lesion is very important in the management
of CHI, it has been reported that imaging studies, including computed tomography (CT), magnetic resonance imaging
(MRI) scans, or angiography, are not helpful in identifying the focal lesion. Currently, fluorine-18-L-dihydroxyphenylalanine
positron emission tomography (18F-DOPA PET) is believed to be the only imaging modality that can identify the focal
lesions. In this report, however, we present a case of a 7-month-old girl with the focal form of CHI, caused by a
loss-of-function mutation in the ABCC8 gene, whose lesion was clearly visible as a hyperenhancing nodule on
contrast-enhanced CT and dynamic MRI imaging.
Background
Congenital hyperinsulinism (CHI) is the most common
cause of persistent hypoglycemia in the neonatal/infantile
period which often requires pancreatectomy when unre-
sponsive to medical treatments [1–7].
There are two known histological forms of CHI: dif-
fuse and focal. The focal form is characterized by a clus-
ter of abnormal insulin-oversecreting β cells within a
restricted area of the pancreas, whereas in the diffuse
form, abnormal β cells are scattered throughout the pan-
creas. Focal CHI arises in individuals with a paternally
inherited monoallelic mutation in one of the genes cod-
ing for pancreatic ATP-sensitive potassium channel
(KATP channel), KCNJ11 or ABCC8, both located side-
by-side in the chromosomal 11p15.1 region [8, 9]. When
a second event of paternal uniparental disomy at
chromosome 11p15 occurs in a β cell during the devel-
opment of the pancreas, that particular cell loses the
KATP channel activity, and also loses the activity of H19
and CDKN1C, which are adjacent imprinted tumor sup-
pressor genes, expressed only from the maternal allele.
Moreover, in 11p15.5, there is an oppositely imprinted
growth factor gene, IGF2, which is expressed only from
the paternal allele. The gene dosage of IGF2 would be
doubled when paternal uniparental disomy takes place.
Consequently, the insulin-oversecreting abnormal β cell
acquires a growth advantage, eventually forming a focus
of abnormal β cells [10–12].
Since the focal form of CHI can be cured by partial
pancreatectomy without postsurgical diabetes mellitus,
when a patient is unresponsive to conservative therapy,
identification of the focal lesion is very important. It has
been reported that imaging studies, including computed
tomography (CT), magnetic resonance imaging (MRI)
scans, or angiography, are not helpful in identifying
focal lesions, since they do not distort the surround-
ing normal pancreatic structure, and also lack signifi-
cant vascularization [13, 14]. Localization of the focal
form, therefore, has been identified only by fluorine-
18-L-dihydroxyphenylalanine positron emission tomog-
raphy (18F-DOPA PET) scans or by invasive diagnostic
procedures such as arterial stimulation with venous
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sampling (ASVS) or transhepatic portal venous sampling
(THPVS) [15–17].
In this report, however, we present a case of a 7-
month-old girl with the focal form of KATP channel CHI
whose lesion was clearly visible as a hyperenhancing
nodule on contrast-enhanced CT and dynamic MRI im-
aging corresponding to the site detected by 18F-DOPA
PET scan.
Case presentation
The patient was a 7-month-old Japanese girl who was
born after 39 weeks of an uneventful pregnancy, with a
birth weight of 3792 g (+2.4 standard deviation [SD])
and length 54 cm (+2.7 SD). Both parents were healthy
and there was no family history of hypo- or hypergly-
cemia. On the second day of life, she presented with
hypothermia associated with hypoglycemia. A diagnosis
of hyperinsulinemic hypoglycemia was made, based on the
characteristic findings at the time of hypoglycemia: plasma
glucose 1.6 mmol/L with serum insulin 26.7 pmol/L,
undetectable ketone bodies, normal lactate, and normal
ammonia. She was unresponsive to diazoxide at a dose of
20 mg/kg/day, and required 8.6 mg/kg/min of intravenous
glucose infusion to maintain normoglycemia. From the
15th day of life, continuous subcutaneous octreotide infu-
sion was started, and at 25 μg/kg/day of octreotide, glu-
cose infusion could be stopped. However, hypoglycemic
episodes persisted quite often despite frequent feedings.
Fortunately, her psychosocial growth and psychomotor
development remained within the normal range despite
frequent hypoglycemic episodes.
Mutational analysis revealed that she had a paternally
inherited monoallelic mutation in the ABCC8 gene
(c.2506C > T, p.Arg836*). 18F-DOPA PET performed at 4
months of age revealed focal uptake in a single region in
the head of the pancreas (Fig. 1). Based on these results,
surgical resection of the focus was scheduled at 7
months of age. Since an enlargement in the head of the
pancreas was suspected by preoperative abdominal ultra-
sound, further studies using other imaging modalities
were performed. Unexpectedly, a contrast-enhanced CT
scan revealed a clearly enhancing nodule at the head of
the pancreas, corresponding to the site of the focus de-
tected by the 18F-DOPA PET scan (Fig. 2). Dynamic
MRI imaging also detected a hyperenhancing nodule on
the arterial phase. On T1- and T2-weighted imaging, the
nodule showed an isointense signal, compared with the
surrounding pancreatic parenchyma.
On laparotomy, a firmer focal lesion, measuring
about 9 mm in diameter, was visible in the head of
the pancreas which could be easily resected (Fig. 3).
Microscopically, the lesion contained hyperplastic is-
lets separated by thin fibrovascular bands. The islets
were adenoma-like, and some of the β cells within
the lesion had enlarged nuclei typical of the focal
form of CHI (Fig. 4). Insulin immunostaining showed
increased insulin producing β cells within the lesion
(Fig. 4). The islets in the surrounding pancreas were
normal.
DNA was extracted from the abnormal islets obtained
by laser microdissection. Sequencing analysis of the
ABCC8 gene revealed predominance of a mutated pater-
nal allele from these abnormal islets, confirming the
diagnosis of the focal form of KATP channel CHI (Fig. 5).
Fig. 1 18F-DOPA PET scan. A focal lesion was identified in the head
of the pancreas (arrow)
Fig. 2 CT scan. A hyperenhancing nodule was identified on the arterial phase
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Molecular analysis
Mutational analysis was performed as described previ-
ously [18]. Briefly, all exons and exon-intron boundaries
of the KATP channel genes were amplified from genomic
DNA and directly sequenced. Laser microdissection was
performed using the Arcturus PIXCELL IIe (Life
Technologies, Carlsbad, CA) instrument, as described
in the manufacturer instructions. The study protocol
was approved by the Institutional Review Board (No. 743),
and written informed consent was obtained from the
guardians of the patient.
Discussion
Contrary to the previous belief, our report shows that
some of the focal KATP-channel CHI can be visualized
by conventional imaging modalities such as contrast-
enhanced CT or dynamic MRI imaging. Although CT
scans are not advisable for infants in view of the risk of
irradiation, MRI imaging might be worth trying espe-
cially where 18F-DOPA PET scans are not easily
available.
The reason why the focal lesion of our patient could
be clearly visualized by contrast-enhanced CT and MRI
scans is not clear. Generally, for pancreatic nodules to
be visualized by these imaging modalities, they need to
grow fast enough to have a mass effect. In addition, they
need to have a higher vascularity, or higher vascular per-
meability, to be enhanced by the contrast media. The
focal lesion of our patient somehow attained both of
these properties. In contrast, the size and cell density of
the lesion do not appear to be critical factors for
visualization by these techniques [19, 20].
Since the tumor suppressor activity of our patient is
presumed to be lost as in all other cases of focal CHI,
the higher growth potential of the focal lesion in this
case might be explained by a difference in the growth
promoting activity of the IGF2 gene, although no
Fig. 3 Macroscopic finding of the focus. A nodule with a clear
margin was identified in the head of the pancreas at laparotomy
Fig. 4 Histological findings of the resected focus. a Hematoxylin eosin staining (×400). Some of the β cells within the lesion had enlarged nuclei
(arrow). b Insulin staining (× 400). An increased number of insulin-positive β cells were observed within the lesion
Fig. 5 Mutational analysis of the ABCC8 gene. a DNA obtained
from the peripheral blood leukocytes of the patient. A c.2506C > T
mutation was detected in the heterozygous state with the wild
type allele. The mutation was found to be of paternal origin
(data not shown). b DNA obtained from the focus by laser
microdissection. A loss of the wild type maternal allele was evident.
The reduced peak of the wild type allele probably reflects the normal
tissue within the focus
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mutations could be identified in the coding region of
IGF2 in our patient (data not shown).
Microscopically, the vascularity in the focal lesion of
our patient was not particularly different from that of
other patients with the focal form of CHI. However, if
the focal lesion has higher growth potential, capillary
dilatation without angiogenesis could follow [21], which
might explain the contrast enhancement observed in our
patient.
Conclusions
We report the unprecedented findings in a case of a
focal form of CHI whose lesion was clearly visible as a
hyperenhancing nodule on contrast-enhanced CT and
dynamic MRI imaging. The mechanism leading to the
visualization of the focal lesion in our patient needs
further investigation.
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